| Basics |
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class drugs directed against nuclear transport and related targets to treat cancer and other diseases.
|
| IPO Date: |
November 6, 2013 |
| Sector: |
Healthcare |
| Industry: |
Drug Manufacturers |
| Market Cap: |
$57.23M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.39 | 3.43%
|
| Avg Daily Range (30 D): |
$0.27 | 5.09%
|
| Avg Daily Range (90 D): |
$0.24 | 4.70%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1M |
| Avg Daily Volume (30 D): |
.14M |
| Avg Daily Volume (90 D): |
.11M |
| Trade Size |
| Avg Trade Size (Sh.): |
147 |
| Avg Trade Size (Sh.) (30 D): |
119 |
| Avg Trade Size (Sh.) (90 D): |
121 |
| Institutional Trades |
| Total Inst.Trades: |
2,344 |
| Avg Inst. Trade: |
$1.64M |
| Avg Inst. Trade (30 D): |
$.95M |
| Avg Inst. Trade (90 D): |
$.95M |
| Avg Inst. Trade Volume: |
.01M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.88M |
| Avg Closing Trade (30 D): |
$9.51M |
| Avg Closing Trade (90 D): |
$9.51M |
| Avg Closing Volume: |
15.91K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
|
$-4.32
|
$-2.77
|
|
Diluted EPS
|
|
$-4.32
|
$-2.77
|
|
Revenue
|
$
|
$ 37.93M
|
$ 30.02M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -37.25M
|
$ -23.46M
|
|
Operating Income / Loss
|
$
|
$ -24.39M
|
$ -33.26M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ -23.73M
|
$ -.01M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Feb 26, 2025:
1:15
|
|
|
|
